Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

Abstract Background In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. Me...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri, James Larkin
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2018-12-01
Σειρά:	BMC Cancer
Θέματα:	Axitinib Cabozantinib Everolimus Indirect comparison Matching-adjusted comparison mRCC
Διαθέσιμο Online:	http://link.springer.com/article/10.1186/s12885-018-5157-0
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!